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For all adeno-associated virus (AAV) serotypes, 60 monomers of the Vp1, Vp2, and Vp3 structural proteins
assemble via an unknown mechanism to form an intact capsid. In an effort to better understand the properties
of the capsid monomers and their role in viral entry and infection, we evaluated whether monomers from
distinct serotypes can be mixed to form infectious particles with unique phenotypes. This transcapsidation
approach consisted of the transfection of pairwise combinations of AAV serotype 1 to 5 helper plasmids to
produce mosaic capsid recombinant AAV (rAAV). All ratios (19:1, 3:1, 1:1, 1:3, and 1:19) of these mixtures were
able to replicate the green fluorescent protein transgene and to produce capsid proteins. A high-titer rAAV was
obtained with mixtures that included either serotype 1, 2, or 3, whereas an rAAV of intermediate titer was
obtained from serotype 5 mixtures. Only mixtures containing the AAV4 capsid exhibited reduced packaging
capacity. The binding profiles of the mixed-virus preparations to either heparin sulfate (HS) or mucin agarose
revealed that only AAV3-AAV5 mixtures at the 3:1 ratio exhibited duality in binding. All other mixtures
displayed either an abrupt shift or a gradual alteration in the binding profile to the respective ligand upon
increase of a capsid component that conferred either HS or mucin binding. The transduction of cell lines was
used to further evaluate the phenotypes of these transcapsidated virions. Three transduction profiles were
observed: (i) small to no change regardless of ratio, (ii) a gradual increase in transduction consistent with
titration of a second capsid component, or (iii) an abrupt increase in transduction (threshold effect) dependent
on the specific ratios used. Interestingly, an unexpected synergistic effect in transduction was observed when
AAV1 helper constructs were combined with type 2 or type 3 recipient helpers. Further studies determined that
at least two components contributed to this observed synergy: (i) heparin-mediated binding from AAV2 and (ii)
an unidentified enhancement activity from AAV1 structural proteins. Using this procedure of mixing different
AAV helper plasmids to generate “cross-dressed” AAV virions, we propose an additional means of classifying
new AAV serotypes into subgroups based on functional approaches to analyze AAV capsid assembly, receptor-
mediated binding, and virus trafficking. Exploitation of this approach in generating custom-designed AAV
vectors should be of significant value to the field of gene therapy.
Adeno-associated virus (AAV), a member of the Parvoviridae
family, is utilized as a virus vector for gene therapy. Eight
different AAV serotypes have been described (6, 7, 12, 32, 43).
Of these, AAV serotype 2 (AAV2) is the most studied and the
only one used in gene therapy clinical trials to date (19, 21).
The genomes of AAV serotypes are similar, consisting of two
large open reading frames (ORFs) that are flanked by inverted
terminal repeats (ITRs) (reviewed in references 24 and 25).
The ITRs are the genetic elements responsible for the repli-
cation and packaging and the only cis elements required to
generate recombinant AAV (rAAV). The left ORF encodes
the four replication proteins (rep78, rep68, rep52, and rep40)
responsible for site-specific integration, nicking activity, heli-
case activity, and regulation of AAV promoters.
The viral structural proteins (VP1, VP2, and VP3) that as-
semble into the virion shells are encoded by the right ORF.
The first step in the viral infection process, cell attachment, is
mediated by the interaction of specific regions on the capsid
shell with cellular receptors and coreceptors (28, 36, 37). A
pivotal contribution to the understanding of the molecular
events that mediate attachment is the recent publication of the
crystal structure of AAV2 (45). This information, in conjunc-
tion with mutational analyses of the AAV2 capsid, has allowed
the identification of functional domains of the AAV2 capsid
involved in binding to the primary cell surface receptor, hepa-
ran sulfate (HS) (23, 26, 31, 34, 42). Additional properties of
viruses that can be attributed to the capsid include pathways
for internalization and uncoating and immediate cellular re-
sponses to the capsid (4, 9, 10, 33). Unfortunately, these activ-
ities have yet to be mapped to specific regions of the capsid of
any AAV serotype.
The driving force behind the manipulation of the AAV
virion shell is to map and understand the contribution of the
capsid amino acids, as well as to exploit this information to
alter the tropism or transduction efficiency. Several studies
have used a rational design method to insert or exchange small
epitopes into the capsid shell predicted as a means of retar-
geting AAV and thereby altering the tropism (3, 13, 14, 27, 35,
42). These methods have met with various degrees of success.
Others have proposed to utilize the preexisting differences of
tropism between the serotypes (8, 30, 40). The serotypes of
AAV exhibit specific phenotypes, as exemplified by their bind-
ing to particular cell surface receptors. For example, AAV2
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and AAV3 bind to HS; however, their elution profiles are quite
distinct, suggesting that these viruses interact differently (29).
In contrast, AAV4 and AAV5 do not interact with HS but
instead interact with sialic acid moieties, albeit via different
linkages (22, 39). Furthermore, AAV1 does not appear to
utilize HS, and its receptor and binding activity remain un-
known. The recently described serotypes 7 and 8 have no
known receptor, but since they closely resemble AAV1, except
for the hypervariable region, they may share a common recep-
tor (12). In an effort to further understand the infectious pro-
cess of the various serotypes, investigators have swapped re-
gions between serotypes within one subunit of the capsid,
forming chimeric viruses homogenous in nature, by utilizing
standard cloning techniques (18) or, in one case, by using a
marker rescue approach (5).
Since more AAV serotypes are being isolated each year, the
task of understanding serotype-specific infection with the long-
term goal of developing more efficient and safer AAV vectors
requires a focused effort on basic AAV virology. One approach
to assist in classifying and understanding distinct phenotypes of
specific AAV serotype and utilize this information to further
evolve AAV as a viral vector is to generate rAAV with mixed
or mosaic capsid shells (17). We undertook a comprehensive
approach and mixed all combinations of available serotype
plasmids (AAV1 to AAV5) at five ratios to control the final
contribution of serotype-specific capsid components in the ma-
ture virion. Some of the properties of the two serotypes may be
shared (17), some may be masked, and some may be dominant
depending on the ratio of helper plasmids used. Most impor-
tantly, positive attributes of the two serotypes may be additive
or synergistic in tests for viral transduction. Such possibilities
were investigated both in vitro and in cell culture, and both
expected and unexpected results were obtained at particular
ratios of helper plasmids. Mixing different AAV helper plas-
mids to generate “cross-dressed” AAV virions can be applied
to any and all AAV serotypes and should facilitate a basic
understanding of AAV capsid assembly, receptor-mediated
binding, and virus trafficking, attributes essential for vector
development.
MATERIALS AND METHODS
Cells and plasmids. The six cell lines utilized in the present study are available
from the American Type Culture Collection. All were maintained at 37°C with
5% CO2 in their respective media, which was supplemented with 10% fetal
bovine serum and penicillin-streptomycin. 293 HEK and HeLa cells were grown
in Dulbecco modified Eagle medium (DMEM). CHOK1, CHO-pgsD, and CHO-
pgsE, cells were grown in Ham F-12 medium. C2C12 cells were grown in minimal
essential medium alpha.
The AAV serotype helper plasmids pXR1-5, as well as the plasmid pXX6-80,
have been described elsewhere (29, 44). The H/N3761 and H2634 mutant AAV2
helper plasmids were described previously (31). Essentially, in the H/N3761
mutant, 12 bp encoding the amino acids AISP was inserted at position 3761 of
the AAV2 genome. The H2634 mutant consisted of a 12-bp insertion encoding
the amino acids GDIA at AAV2 nucleotide position 2634.
Recombinant virus production. Recombinant AAV was produced by using a
modified triple plasmid transfection protocol (15). A 15-cm dish of 293 HEK
cells (ca. 2  107) was transfected by using Superfect reagent according to
the manufacturer’s instructions (Qiagen, Valencia, Calif.) with 7 g of
pTRCMVeGFP, 15 g of XX6-80, and 10 g of the serotype helper plasmid. To
generate AAV virions containing capsid components of different serotypes, the
amount of each helper plasmid transfected was varied depending on the ratio
being assessed. For example, if AAV3 and AAV4 were mixed at a ratio of 19:1,
then 9.5 g of pXR3 and 0.5 g of pXR4 were added to the transfection mixture.
The cells were harvested at 48 to 52 h posttransfection by scraping, and all
subsequent manipulations were performed on ice unless otherwise noted. One-
fifth of the cell lysate was set aside for Hirt DNA isolation (see below), while the
remainder was subjected to low-speed centrifugation and resuspended in a so-
lution of 3 g of leupeptin/ml. The cell lysate was subjected to sonication under
previously described conditions (31). A portion of the cell lysate was removed for
the Western blot analyses described below. Benzonase (Sigma, St. Louis, Mo.)
was added to the remainder at a final concentration of 1.2 U/l, followed by
incubation at 37°C for 30 to 60 min. Then, 0.58 g of cesium chloride was added
to each milliliter of lysate, and the mixtures were centrifuged for 4 h at 100,000
rpm in a TLN 100 rotor in the Optima TLX ultracentrifuge (Beckman, Palo Alto,
Calif.). Peak fractions from the gradient were determined by dot blot hybridiza-
tion as previously described (31) by using a radiolabeled green fluorescent pro-
tein (GFP) probe.
Hirt assay. DNA from the infected cell lysate was isolated as described by Hirt
(20). Approximately 3 g of DNA from each sample was digested with DpnI,
fractionated on an agarose gel, transferred to a Nytran membrane, and probed
with the GFP transgene.
Western blot analyses. The protein concentration of transfected cell lysates
was determined by the BCA protein assay (Pierce, Rockford, Ill.). Five micro-
grams of total protein was loaded in each lane, followed by separation by
electrophoresis on a NuPage 10% polyacrylamide Bis-Tris gel (Invitrogen, Carls-
bad, Calif.) and then transfer to a Hybond ECL membrane (Amersham Phar-
macia Biotech, Piscataway, N.J.). The membrane was probed with either the B1
monoclonal antibody (41) specific for AAV capsid proteins or the Living Colors
Anti-GFP monoclonal antibody (Clontech, Palo Alto, Calif.). The proteins were
visualized by using a peroxidase-coupled secondary antibody and the Supersignal
WestFemto kit (Pierce).
Electron microscopy. Peak fractions of rAAV1/5 and rAAV2 were placed on
a 400-mesh glow-discharged carbon grid by inverting on a 10-l drop of virus.
The grid was washed three times in 1 phosphate-buffered saline (PBS) for 1
min. The virus was then stained for 1 min with 2% phosphotungstic acid. The
virus was visualized by using a Zeiss EM 910 electron microscope.
Heparin-binding assays. Batch binding of rAAV to heparin agarose was per-
formed as described previously (31). Briefly, equivalent particles of parental and
mixed rAAV virions were applied to heparin agarose type 1 (H-6508; Sigma) in
1 PBS, allowed to bind for 1 h at room temperature, and centrifuged at low
speed for 2 min, and supernatant (flowthrough) was then removed. Six washes of
five bed-volumes of PBS–1 mM MgCl2 were performed, followed by a three-step
elution of five bed-volumes of PBS–1 mM MgCl2 containing 0.5 M NaCl (step 1),
1.0 M NaCl (step 2), or 1.5 M NaCl (step 3). The numbers of rAAV particles
present in the washes and the three-step elution were determined by dot blot
hybridization.
Mucin-binding assays. Mucin (Sigma) was linked to agarose as described by
the manufacturer. Parental and mixed rAAV virion binding was determined in a
manner analogous to that described above for heparin binding.
Flow cytometry. For analysis of GFP expression, the cell lines pgsD, pgsE,
CHOK1, C2C12, and HeLa (n  5  105) were transduced in quadruplicate with
300 or 3,000 vector genomes (vg) of the parental or mixed rAAV/cell and were
additionally infected with Ad dl309 at a multiplicity of infection (MOI) of 14. At
24 h posttransduction, cells were harvested and scored for GFP expression by
using the FacSCAN 1 flow cytometer (Becton Dickinson, Franklin Lakes, N.J.).
Some variation was observed between experiments possibly due to differences in
gating, age of the adenovirus preparation, or even the passage number of the cell
lines.
Heparin inhibition assay. The ability of soluble HS to inhibit the binding of
rAAV1 and rAAV2 to C2C12 cells was assayed as described previously (37).
Briefly, rAAV1/2, rAAV1, or rAAV2 at 300 vg/cell was incubated in DMEM in
the presence or absence of soluble HS at 30 g/ml for 1 h at 37°C. Concurrently,
C2C12 cells were incubated for 1 h in DMEM in the presence or absence of
soluble HS. After the preincubation steps, the C2C12 cells were infected for 1 h
with their respective rAAV preparations and additionally coinfected with ade-
novirus dl309 (Ad dl309) at an MOI of 14. At 24 h posttransduction, cells were
harvested and scored for GFP expression as described above. Analogous meth-
ods were used to assess the ability of soluble HS to inhibit binding of rAAV3/5
to HeLa cells.
Neuraminidase assay. The ability of neuraminidase treatment of HeLa cells to
prevent infection of rAAV3/5 was assayed. Briefly, HeLa cells were pretreated
for 1 h at 37°C with 10 U of neuraminidase (Sigma)/ml/h. After the preincubation
step, HeLa cells were infected for 1 h with the respective rAAV preparation
(3,000 vg/cell) and coinfected with Ad dl309 at an MOI of 14. At 24 h posttrans-
duction, cells were harvested and scored for GFP expression as described above.
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RESULTS
Design parameters of AAV serotype mixing. The feasibility
of mixing capsid proteins from different AAV serotypes was
investigated by using the previously characterized AAV2
helper plasmid mutants H2634 and H/N3761 (31). Both helper
plasmids produce noninfectious virions as a result of unique
mutations in their capsid regions. Virus produced from the
H/N3761 mutant contains all three capsid subunits (VP1, VP2,
and VP3); however, this virus does not bind heparin, nor will it
compete with wild-type AAV2 for transduction into cells. The
H2634 mutant produces virus with only VP3 subunits that will
bind heparin and has the ability to compete with wild-type
AAV2 for transduction into cells but is not infectious. When
these two helper plasmids are mixed at different ratios during
the transfection stage of recombinant AAV2 production, in-
fectious virus was obtained as judged by the ability to transduce
HeLa cells (Table 1). These results indicated that the viable
virions were not assembled homogeneously from the capsid
subunits of one mutant but were instead composed of mixtures
of subunits from each mutant. Importantly, these initial exper-
iments indicated that advantageous phenotypes of each mutant
could be built into a mosaic virus (Fig. 1) and further suggested
that properties of different AAV serotypes might be able to be
mixed in an analogous manner.
To investigate the possibility of serotype capsid mixing,
helper plasmids containing the five currently available serotype
capsid genes (AAV1 to AAV5) (29) were mixed pairwise at
specific ratios of 19:1, 3:1, 1:1, 1:3, and 1:19 (Fig. 1). These
helper plasmids have the same genetic backbone, efficiently
replicate transgenes, produce replication and capsid proteins
at nearly the same level, and package transgenes with AAV2
ITRs. As a result of these similarities and the number of DNA
molecules used in the transfection (1.12  1012 in 10 g), the
number of molecules of each helper plasmid entering each cell
should vary only slightly around the specific ratio. The resulting
virions should be composed of subunits from each serotype
used in the pairwise transfection mixture, and the ratio would
determine the general composition of these virions (Fig. 1).
For nomenclature purposes, the mixtures are reported as frac-
tions in which the numerator represents the first parent plas-
mid and the denominator represents the second parent. Ac-
cordingly, the first number in the ratio corresponds to the first
FIG. 1. Plasmid mixing approach used to generate transcapsidated rAAV. Helper plasmid DNA containing the capsid gene from any two AAV
serotypes (one is represented by a red capsid gene, and the other is represented by a blue capsid gene) was cotransfected at different ratios (19:1,
3:1, 1:1, 1:3, and 1:19) during the standard production scheme to generate rAAV particles. The topology maps of potential viral products are shown
and colored according to the proportion of subunits from the ratio of helper plasmids in the transfection mixtures.








H2634 100% 1.24 0
9:1 0.79 3.6  104
H2634:H/N3761 4:1 1.01 1.4  104
7:3 1.47 1.0  104
3:2 1.48 1.2  105
1:1 1.02 1.9  105




H/N3761 100% 2.77 0
a Viral samples were described elsewhere (31).
b Ratio refers to the mixing of helper plasmids during the transfection.
c From each sample, 2.5  108 viral genomes were used to transduce 3  105
HeLa cells in triplicate. TU, transducing unit.
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parent, and the second number in the ratio corresponds to
second parent. For example, a mixed-virus preparation con-
sisting of 25% AAV1 plasmid and 75% AAV2 plasmid would
be referred to as AAV1/2 with a ratio of 1:3.
Physical characterization of mixed virions. Control experi-
ments were performed to examine the potential for recombi-
nation of the helper plasmid pairs. Hirt DNA was isolated at
48 h posttransfection and transformed into Escherichia coli,
and individual plasmids were assessed to determine whether
recombination between serotype plasmids occurred. After nu-
merous colonies from separate transfections were screened by
restriction digestion, no evidence was found for recombination
(data not shown).
Dot blot analyses were performed on cesium gradient puri-
fied samples from the 50 AAV mixing combinations, as well as
the five serotype control samples, to determine whether the
resultant viruses could package the GFP transgene. A sample
of the peak fraction from each mixture is shown (Fig. 2A), and
the corresponding physical titers are presented in Table 2.
Three general classes of capsid interactions were identified
from this type of analyses. Class A mixtures consist of sero-
types that mix well at all ratios examined and generate titers
almost equivalent to their respective 100% controls. In these
experiments, class A mixtures consisted of any AAV1, AAV2,
FIG. 2. (A) Dot blot of peak fractions from cesium gradient-purified AAV mixtures. 293 cells were transfected with AAV1 to AAV5 plasmids
(AAV column) or combinations of the five serotypes (AAV serotype mixtures 1/2, 1/3, 1/4, 1/5, 2/3, 2/4, 2/5, 3/4, 3/5, and 4/5) at differing ratios
(19:1, 3:1, 1:1, 1:3, and 1:19). The fractions on top of the blot indicate the AAV serotype helper plasmid contributors in the mixture and the ratios
on the left side of the blot correspond to the relative amounts of all contributors in the mixture, respectively. Portions (2 l) from the peak fraction
of each cesium-purified virus preparation were applied to a GeneScreen Plus membrane and then probed with the GFP transgene that had been
random primed. Duplicate DNA controls of the plasmid transgene are shown at the bottom of the blot. (B) Hirt DNA Southern blot analyses of
AAV1/2, AAV1/3, AAV1/4, and AAV1/5 mixtures. 293 cells were transfected with either the AAV1 to AAV5 helper plasmids (AAV serotype
lanes) or all ratios (19:1, 3:1, 1:1, 1:3, and 1:19) of the AAV1/2, AAV1/3, AAV1/4, and AAV1/5 helper plasmids to produce rAAV. Low-molecular-
weight DNA was isolated 48 h posttransfection, and a portion was digested with DpnI. Then, 3 g of DpnI-digested (top panel) or undigested
(bottom panel) DNA was separated via a 1% agarose gel (M lane, DNA ladder). After transfer, the blot was probed with a random-primed GFP
transgene. (C) Analyses of capsid protein composition from the AAV1/4 mixtures. Protein lysates from the transfection of either the AAV1 and
AAV4 helper plasmids alone or mixed at different ratios (19:1, 3:1, 1:1, 1:3, and 1:19) were resolved by sodium dodecyl sulfate–10% polyacrylamide
gel electrophoresis and transferred to a membrane. The blot was probed with either the B1 monoclonal antibody (top panel) directed against the
carboxyl termini of the AAV2 VP3 protein or an anti-GFP antibody (bottom panel). (D) Transmission electron microscopy. Peak dot blot fractions
of the AAV1/5 mixed virions (1:3 ratio) and rAAV2 were stained in 2% phosphotungstic acid and imaged by transmission electron microscopy.
Arrows indicate potential fivefold capsid subunits.
TABLE 2. Particle numbers for AAV pseudotypes and controlsa
Ratio
No. of particles (1012)/ml for AAV serotype mixture:
1/2 1/3 1/4 1/5 2/3 2/4 2/5 3/4 3/5 4/5
19:1 2.56 1.95 1.160 0.168 0.602 0.278 0.246 0.364 0.047 0.027
3:1 2.42 2.10 0.115 0.079 0.813 0.029 0.125 0.022 0.085 0.077
1:1 2.40 1.59 0.027 0.103 0.660 0.011 0.151 0.004 0.146 0.133
1:3 2.36 0.97 0.018 0.155 1.010 0.011 0.190 0.006 0.172 0.070
1:19 2.27 1.64 0.128 0.280 0.884 0.068 0.240 0.066 0.144 0.081
a For unmixed AAVs 1, 2, 3, 4, and 5, the values were 0.858  1012, 1.840 
1012, 1.760  1012, 0.836  1012, and 0.237  1012 particles/ml, respectively.
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or AAV3 combination. Class B mixtures consist of interactions
of AAV5 with serotypes 1, 2, 3, and 4. The physical titers from
all of these mixtures were of intermediate numbers and were
similar to the AAV5 parental 100% control (see Table 2).
Class C mixtures were composed of the serotypes (AAV1,
AAV2, and AAV3) that do not mix very well with AAV4, as
evidenced by the drastic reduction in physical titer of these
mixtures outside of the 19:1 and 1:19 ratios.
To eliminate the possibility that problems other than aber-
rant packaging of the transgene were responsible for the poor
performance of the class C mixtures, additional physical prop-
erties of the mixed viruses or its corresponding transfection
lysate were examined. The presence of replicating transgene
DNA in all mixed and parental rAAV preparations was con-
firmed by analyses of Hirt DNA (Fig. 2B; AAV1/2, AAV1/3,
AAV1/4, and AAV1/5 are shown). These results clearly dem-
onstrate that replicating genomes were present at similar levels
in transfection lysates of all mixed virus preparations, including
those that produced low particle numbers.
Western blot analyses were performed on equivalent protein
amounts from transfected cell lysates from each helper plasmid
mixture ratio by using monoclonal antibodies against the AAV
structural proteins or the GFP protein as a control (Fig. 2C,
AAV1/4 mixtures are shown). The B1 monoclonal antibody
recognizes the capsid proteins of all serotypes with the excep-
tion of AAV4 (29). Western blot analyses with this antibody on
cell lysates from the AAV1/4 mixing experiments indicated
that, as the contribution of AAV4 increases to 1:19, the ability
of the antibody to recognize the capsid is lost. This absence in
antibody recognition does not correlate with the loss of dot
blot signal, which decreases as the contribution of AAV4 sub-
units increases toward the 1:1 ratio (Fig. 2A, see 1/4, 2/4, and
3/4 mixtures).
Electron microscopy was used to examine the physical par-
ticles of the three classes of mixed virions. Class A virions were
indistinguishable from preparations of AAV2 virions at the
resolution viewed, whereas no intact particles were observed
from preparations of class C virions of intermediate ratio of 1:1
(data not shown). This further suggests that the lack of a dot
blot signal in class C virus preparations does not represent an
absence of subunits or packageable genomes but rather an
inability to assemble capsids with the type and proportion of
the capsid subunits present. Class B mixed viruses (AAV1/5
[1:3] shown as an example) were indistinguishable from AAV2
FIG. 3. Heparin batch binding profiles of rAAV mixed virions. Totals of 1010 vg of each ratio (19:1, 3:1, 1:1, 1:3, or 1:19) of the rAAV1/2,
rAAV1/3, rAAV2/3, rAAV2/5, and rAAV3/5 mixed virions or the rAAV1, rAAV2, or rAAV3 viral controls were applied to 50 l of heparin
agarose, washed, and eluted as described in Materials and Methods. Equal percentages of the total volume from each fraction were subjected to
dot blot analyses and probed with the GFP transgene. The data are represented in pie charts and indicate the percent virus that bound (dark gray
slices) or did not bind (light gray slices) to heparin.
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(Fig. 2D); however, smaller components were evident in these
preparations (Fig. 2D, arrows) and may represent incompletely
assembled or unassembled capsid components. These smaller
entities were not observed in preparations of AAV2 (Fig. 2D,
AAV2).
In vitro binding properties of mixed virus. It has been shown
that AAV2 and AAV3 bind heparin agarose (29, 37) and that
both AAV4 and AAV5 bind mucin (1, 38). To determine
whether the mixed virions exhibit binding properties similar to
the parental virions or whether the binding to both heparin and
mucin can be coupled through mixing of capsid components,
the binding properties of each ratio of all mixtures except the
1/4, 2/4, and 3/4 mixed viruses that were deficient in generating
sufficient test material were examined.
Equivalent particles of parental and all ratios of mixed viri-
ons were applied to either a heparin agarose or a mucin col-
umn, washed, and eluted in three steps of increasing salt.
Samples from each column fraction were analyzed by dot blot
analyses, and the corresponding percentages of bound and
unbound virus are presented as pie charts (Fig. 3 and 4).
Class A mixed viruses interacted on the heparin column in
two manners: either as an abrupt shift (Fig. 3A to E) or as a
gradual change (Fig. 3G to K) in the heparin-binding profile
upon increase of the second capsid component. Less than 10%
of the AAV1/2 (19:1) mixture bound to heparin (Fig. 3A).
Heparin binding abruptly changed to 75% at the 3:1 ratio
(Fig. 3B). This finding is in contrast to AAV1/3 mixed viruses,
with which there was a gradual change in heparin binding:
25% binding at the 3:1 ratio increasing to 50% at 1:1 ratio to
90% at the 1:3 ratio (Fig. 3H, I, and J). As expected, all ratios
of the AAV2/3 mixtures bound heparin (Fig. 3M to Q).
Since neither AAV4 nor AAV5 bound heparin, the heparin-
binding profiles were not determined for the AAV1/5 and
AAV4/5 mixtures. In the case of the other class B interactions,
the heparin-binding profiles of the AAV2/5 and AAV3/5 mix-
tures were essentially identical (Fig. 3S to BB); the 19:1 ratios
were the only mixtures that significantly bound to heparin (Fig.
3S and X). Heparin-binding analyses of the class C mixes could
not be determined because of the low particle numbers.
Mucin-binding experiments with class A parental or class A
mixed virus did not result in significant mucin binding, as
expected (data not shown). Interactions of class C mixtures on
the mucin column could not be determined since these mix-
tures did not contain sufficient viral particles.
The mucin-binding profiles for the AAV1/5 and AAV3/5
mixtures resemble their respective parents in the extreme ra-
FIG. 4. Mucin batch binding profiles of rAAV mixed virions. Totals of 109 vg of each ratio (19:1, 3:1, 1:1, 1:3, or 1:19) of the rAAV1/5, rAAV2/5,
rAAV3/5, and rAAV4/5 mixed virions or the rAAV1 to rAAV5 viral controls were applied to 50 l of mucin agarose, washed, and eluted as
described in Materials and Methods. Equal percentages of the total volume from each fraction were subjected to dot blot analyses and probed with
the GFP transgene. The data are represented in pie charts and indicate the percent virus that bound (dark gray slices) or did not bind (light gray
slices) to mucin.
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tios (19:1 and 1:19; Fig. 4A, M, E, and Q). These mixtures at
the 1:1 ratio bind to mucin more efficiently than AAV5 (Fig.
4C and O). AAV4/5 mixed viruses bound mucin as expected,
since both parental serotypes individually bound mucin. Inter-
mediate ratios of AAV4/5 (3:1, 1:1, and 1:3) appear to bind
mucin better than either parent or the more extreme ratios
19:1 and 1:19 (Fig. 4S to W). Interestingly, only AAV3/5 (3:1)
was able to bind both mucin and heparin agarose (Fig. 3Y and
4N). To determine whether individual particles bound both
mucin and heparin agarose, a preparation of AAV3/5 (3:1) was
used to first bind mucin. Virus eluted from this column was
then used to bind heparin. The results from this experiment
indicate that the AAV3/5 (3:1) preparation was able to bind
both matrices at levels similar to those shown in Fig. 3Y and
4N. The control viruses (AAV3 and AAV5) were not able to
successively bind the different matrices, indicating that the
individual mosaic particles of AAV3/5 (3:1) were dual binders
due to assembly of virus particles composed of mixed parental
(types 3 and 5, respectively) capsid components (data not
shown).
Both heparin competition and neuraminidase treatment of
cells were used to assess whether this binding duality corre-
lated with cell infection. Heparin pretreatment was unable to
inhibit AAV3b (Fig. 5). This was unexpected since Handa et al.
(16) previously demonstrated that AAV3a is inhibited by sol-
uble heparin at these concentrations. The same concentration
of heparin was able to inhibit the ability of rAAV2 to transduce
C2C12 cells (see Fig. 7B). As expected, the ability of rAAV5 to
transduce HeLa cells was greatly reduced upon pretreatment
with neuraminidase, whereas the ability of rAAV3 to transduce
these cells was unaffected (Fig. 5). More importantly, the
AAV3/5 (3:1) mixture was reliant only on sialic acid for infec-
tivity, as judged by the decrease in transduction of cells pre-
treated with neuraminidase (Fig. 5).
Transduction of different cell lines with AAV mixed virus.
Mixed virus preparations were analyzed for their ability to
transduce human, mouse, and Chinese hamster cell lines. The
CHO wild-type cells, K1, and derivatives with mutations in
glycosaminoglycan biosynthesis (pgsD and pgsE cells) were
selected since these cells demonstrate a biological phenome-
non: heparin-dependent transduction of AAV2 (29, 37). HeLa
cells are the standard line to titer rAAV, and C2C12 cells were
used because they are known to bind AAV2 and yet are re-
fractory to transduction (11). Either 300 or 3,000 vg of the
mixed virus/cell was used in the transduction assays. All trans-
duction assays were performed in the presence of adenovirus
and flow cytometry was used to determine the percentage of
cells expressing GFP.
Four transduction profiles were apparent in these experi-
ments: (i) a gradual change (titration), (ii) little or no change
(plateau), (iii) abrupt changes (threshold), and (iv) synergistic
changes as the amount of input plasmid increased from one
parental serotype to the other (Fig. 6). The titration effect is
seen in HeLa cells for the AAV1/3 (Fig. 6F) and in CHO K1
and pgsE cells for the AAV 2/5 mixtures (Fig. 6R and T). The
plateau effect was observed in C2C12 cells for both the
AAV1/5 and the AAV2/5 mixtures (Fig. 6L and Q). The
threshold effect is clearly seen in HeLa cells infected with the
AAV2/5 mixtures, for which the transduction efficiency de-
creased from 10 to 11% at the 19:1 ratio to 3% at 3:1 ratio (Fig.
6P). This pattern was also seen in HeLa cells with the AAV1/2
mixtures (Fig. 6A), in CHO K1 cells with the AAV1/3 (Fig.
6H) and 1/5 mixtures (Fig. 6M), in CHO pgsD cells with the
AAV1/2 mixtures (Fig. 6D), and in CHO pgsE cells with the
AAV1/5 mixtures (Fig. 6O). Finally, a synergistic pattern was
observed in C2C12, CHOK1, and pgsE cells infected with
vector from AAV1/2 mixtures (Fig. 6B, C, and E) and in
C2C12, pgsD, and pgsE cells infected with vector from
AAV1/3 mixtures (Fig. 6G, I, and J). This pattern resulted in
some ratios of mosaic virus having a better transduction effi-
ciency than either parental virus.
To test that the enhanced transduction observed from mo-
saic virus particles were not an artifact of mixing two parental
serotypes virions, purified recombinant viruses from two sero-
types (AAV1 and AAV2) were mixed at ratios identical to
those used for the helper plasmids, and these mixtures were
used to transduce C2C12 cells, with the same overall particle
number (i.e., 300) that was used in the plasmid mixing exper-
iments. A titration effect was observed in this instance as the
ratio of the virus varied (Fig. 7A), in contrast to the synergistic
effect observed (Fig. 6B) when rAAV1/2 mosaic viruses were
used to transduce C2C12 cells. Based on in vitro binding stud-
ies and in vivo transduction assays, we probed known attributes
of the parental virus to determine a mechanism for the syner-
gism we observed from the mosaic virus particles.
Heparin inhibition of C2C12 cells transduced with AAV1/2
mixed viruses. Heparin competition was used to determine
whether the enhancement in transduction of C2C12 cells by
AAV1/2 mixed viruses was due to HS-mediated binding. Re-
FIG. 5. Neuraminidase and soluble heparan inhibition. HeLa cells,
either untreated (virus) or pretreated with neuraminidase (N) and/or
soluble heparin (H or HN) for 1 h, were transduced with 3,000 vg of
AAV3, AAV5, or AAV3/5 (3:1)/cell. The cells were either untreated
or preincubated with soluble heparin for 1 h (H or HN). After the
completion of all preincubation steps, the respective virus was allowed
to attach to cells and removed 1 h later, and fresh medium was applied.
At 24 h posttransduction, cells were prepared for flow cytometry to
measure the percent GFP expression. The graph indicates the percent
GFP expression, with each bar representing an average of three sep-
arate infections, with the standard deviation indicated by an error bar.
All transductions were performed in the presence of Ad dl309 at an
MOI of 14.
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combinant AAV1/2 or the parental viruses were incubated in
the presence or absence of soluble heparin for 1 h prior to
transduction with 300 vg/cell. Soluble heparin reduced the en-
hanced transduction of 1:1, 1:3, and 1:19 ratios (Fig. 7B).
However, the transduction of these mixtures was not com-
pletely abolished in the presence of HS-like AAV2 control
(Fig. 7B). Instead, these mixtures plateau at levels identical to
the 3:1 ratio, which was a modest enhancement over both
parental viruses 1 and 2 in the presence of heparin. This sug-
gests that not all of the enhancement was due to HS-mediated
binding but rather related to other steps involved in vector
transduction (e.g., coreceptor usage, trafficking, uncoating, or
facilitation of second-strand synthesis [Fig. 8B]).
DISCUSSION
In the present study, AAV serotype helper plasmids mixed
at various ratios were used to “cross-dress” AAV2 DNA tem-
plates into virion particles. Characterization of the virus par-
ticles for titer, receptor binding, and infectivity on specific cell
lines determined at least three classes of AAV based on struc-
tural compatibility.
Previously, we grouped the AAV serotypes into three classes
based on sequence homology (30). Here, we strengthen the
definition of these classes and now propose that these classes
be referred to as AAV subgroups A (AAV1, AAV2, and
AAV3), B (AAV5), and C (AAV4) based on the nomenclature
used for the human adenovirus serotypes. The importance of
this distinction in classification is that the ever-increasing num-
ber of new AAV serotypes will primarily be grouped according
to sequence homology and further refined functionally on the
basis of capsid structural compatibility.
Critical to the interpretation of these experiments was the
ability to confirm that mixed virus particles were generated. A
number of controls were utilized to verify this, including the
complementation and rescue of the mutants through plasmid
mixing (Table 1) and analysis of Hirt DNA after it was cloned
into E. coli to demonstrate recombination was not a factor for
the generation of mixed viruses (data not shown). Western blot
and Hirt analyses (Fig. 2B and C) indicate that the components
necessary to form virions are present (i.e., AAV capsid pro-
teins and monomer genomes) even when intact virions are not
detected (i.e., subgroup A and C mixes). In addition, some
mosaic virions bound to both HS and mucin columns, display-
ing the affinity of the respective parental virus to their putative
receptor substrate (types 3 and 5, respectively). Further, to
ensure transduction observations were the results of cross-
FIG. 6. Transduction efficiency of reference cell lines with mixed rAAV. Cells (cell types are indicated on top) were transduced with all ratios
(19:1, 3:1, 1:1, 1:3, and 1:19) of the rAAV1/3, rAAV1/2, rAAV1/5, or rAAV2/5 mixed virus and their corresponding parental controls (indicated
as 100%). The vg/cell (vg/c) value used for each experiment is indicated in the upper right corner of each panel. At 24 h posttransduction, cells
were assayed for GFP expression via flow cytometry. Percent GFP expression is represented graphically. Each bar represents an average of four
separate infections, with the standard deviation indicated by an error bar. All transductions were performed in the presence of Ad dl309 at an MOI
of 14.
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dressed virions, preparations of premade serotype-specific vi-
rus were mixed at identical ratios, and distinct vector transduc-
tion profiles were generated compared to mosaic particles
from AAV1/2 on C2C12 cells (compare Fig. 7A and B [minus
heparin]). Together, these experiments confirmed the ability to
generate mosaic or transcapsidated virus by mixing different
ratios of helper plasmids.
Transcapsidation provides insight into AAV capsid struc-
ture. Transcapsidation can be utilized as a method to function-
ally define structural relatedness among the serotypes without
having to perform crystallographic studies on all new sero-
types. For example, transcapsidation of subgroup A viruses
(AAV1, AAV2, or AAV3) all resulted in efficient virion pro-
duction (Fig. 2A), indicating that these three viruses are struc-
turally related and that the AAV2 crystal structure (42) can be
used with confidence when modeling changes in the AAV1 and
AAV3 capsids.
In contrast, the viruses of subgroup A, when mixed with
subgroup C (AAV4), inefficiently packaged genomes (Fig. 2A).
Based on the crystal structure of AAV2, the capsid subunits
interact at the two-, three-, and fivefold axes of symmetry to
form stable virions (45). The inability to generate stable virus
between subgroups A and C may reflect the failure of these
structural subunits to interact at one or more of these axes of
symmetry (Fig. 8A). Since this is a functional and not a ho-
mology test, this information could not be derived from the
sequence only. To further support this hypothesis, a compari-
son of the AAV2 and AAV4 crystal structures revealed clashes
between amino acids consistent with our proposed subgroup-
ing (M. Agbandje-McKenna, unpublished data).
Transcapsidation between subgroups A and B generated
reduced the viral titer at all ratios, suggesting an incompatibil-
ity of subunit interaction at only one axis (Fig. 8A). As an
example, the subunits in AAV2/5 transcapsidated virions may
form stable three- and fivefold axes but an unstable twofold
axis. This would require identical subgroup pairing at the two-
fold axis to form stable virions (Fig. 8A). Based on this hy-
pothesis, each pair of AAV5 subunits at the twofold axis would
potentially reduce the affinity for heparin at adjacent threefold
axes (Fig. 8A, threefold). The amino acids responsible for
heparin binding of AAV2 are located near the peaks on the
slope facing the threefold axis of symmetry (23, 26, 45). Xie et
al. proposed that more than one threefold axis of symmetry
may be necessary for physiological binding of heparin, and the
juxtaposition of multiple sites may determine the strength of
the interaction (45). In our mixed AAV2/5 virions, we ob-
served a decrease in heparin binding (Fig. 3S to W), as well as
decreased titers at all ratios, a finding consistent with this
model. In addition, the physical characteristics of the AAV2/5
mixed virions were further supported by transduction experi-
ments on appropriate cell lines showing that the binding ex-
periments were relevant (Fig. 6; 2/5 HeLa [heparin ] and
CHO pgsD [heparin ]). Another prediction based on this
model would be an accumulation of partially assembled sub-
units, a by-product of this structural incompatibility. This pre-
diction was supported by electron microscopic analysis, in
which smaller structures were observed with the AAV1/5
mixed virions and also in subgroup A/B (Fig. 2D, arrows).
Transcapsidation provides insight into AAV binding. The
binding profiles of subgroup A/B mixtures on heparin and
mucin matrices provide insight to the fundamental mechanism
of viral binding. These mixtures bound mucin at all ratios
except 19:1, at which 95% of the virion is composed of sub-
group A subunits. These results indicate that AAV5 binds
FIG. 7. (A) Transduction of C2C12 cells with mixtures of purified rAAV1 and rAAV2 virus. C2C12 cells were transduced with 300 vg of
rAAV1, rAAV2, or both viruses mixed at the following ratios (19:1, 3:1, 1:1, 1:3, and 1:19)/cell. At 24 h posttransduction, cells were assayed for
GFP expression via flow cytometry. The percent GFP expression is represented graphically. Each bar represents an average of three separate
infections, with the standard deviation indicated by an error bar. All transductions were performed in the presence of Ad dl309 at an MOI of 14.
(B) Heparin inhibition of rAAV1/2 mixed virions in C2C12 cells. C2C12 cells and rAAV1, rAAV2, and rAAV1/2 at the following ratios (19:1, 3:1,
1:1, 1:3, and 1:19) were preincubated for 1 h in the presence of 30 g of heparin/ml. After preincubation, virus (300 vg/cells) was allowed to attach
to cells and removed 1 h later, and fresh medium was applied. At 24 h posttransduction, the cells were prepared for flow cytometry to measure
the percent GFP expression. The graph indicates the percent GFP expression, with each bar representing an average of three separate infections
and with the standard deviation indicated by an error bar. All transductions were performed in the presence of Ad dl309 at an MOI of 14.
VOL. 78, 2004 TRANSCAPSIDATION OF AAV SEROTYPES DEFINES SUBGROUPS 4429
FIG. 8. (A) Model of potential interactions between AAV2 and AAV5 capsid subunits. The triangular shapes represent individual subunits of
AAV2 (yellow) or AAV5 (light blue). The heparin-binding domain of AAV2 is represented by black circles near the threefold axis of symmetry,
whereas the corresponding non-heparin-binding domains of AAV5 are represented as red circles. AAV5 subunits can interact at the twofold axis
of symmetry, whereas AAV2 and AAV5 subunits cannot form in a manner compatible with building intact virions (bottom left). The center depicts
two threefold axes of symmetry consisting of a mosaic composed of AAV2 and AAV5 subunits. The twofold axis of symmetry is composed of
interacting AAV5 subunits, which is consistent with virion formation. However, the ability of these threefold axes, composed of AAV2 and
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mucin through a few subunits. However, consistent with pre-
dictions from the AAV2 crystal structure, the corresponding
heparin-binding profiles for subgroup A/B mixtures indicated
that multiple subunits in juxtaposition were needed for heparin
binding. This is evidenced by the loss of heparin binding for
AAV2/5 at a ratio of 3:1 (Fig. 3T).
A biological consequence of the binding phenomenon is
seen in the transduction data of AAV2/5 mixtures on HeLa
cells, which have high levels of HS. As the composition of the
virion changed from predominantly AAV2 at the 19:1 ratio to
more AAV5 at the 3:1 ratio, the ability to transduce HeLa cells
correspondingly dropped from 11 to 3% (Fig. 6P). In con-
trast, the ability of AAV2/5 to transduce an HS-deficient cell
line (CHO pgsD), increased from 2 to 30% as the composi-
tion of the virion changed from type 2 to type 5 (Fig. 6S).
The binding profiles of group A/B mixed virus preparations
to either heparin or mucin agarose revealed that AAV3/5 mix-
tures at the 3:1 ratio exhibited duality in binding. In an effort
to determine whether this dual binding was of biological sig-
nificance, HeLa cells were treated with neuraminidase, and the
virus and cells were treated with soluble heparin (Fig. 5). The
neuraminidase results demonstrated a significant dependence
on sialic acid for transduction, correlating the mucin binding
and transduction data. Interestingly, heparin inhibition was not
observed for either the AAV3 control or the AAV3/5 mosaic
particles (Fig. 5). This unexpected result may be attributed to
amino acid differences between AAV3a, which is inhibited by
heparin (16), and AAV3b, which was used in the present study
and has never been assessed for heparin inhibition (32). A
complete resolution of this observation will require mixed viri-
ons with AAV3a capsid components instead of AAV3b.
Transcapsidation can be used to produce new and novel
AAV vectors. A potential outcome from the transcapsidation
experiments is that mixed viruses may exhibit a tropism distinct
from either parent or that minor components may have signif-
icant influence on the properties of these cross-dressed virions.
This is clearly seen in the unexpected enhancement in trans-
duction of some cell lines when the AAV1 helper construct was
combined with AAV2 or AAV3 helpers (Fig. 6B, C, E, G, I,
and J). This synergy in transduction efficiency may result from
sharing advantageous phenotypes from each of the parental
serotypes. Alternatively, a unique property could result from a
juxtaposition of subunits from different parents at a specific
ratio or at a specific axis of symmetry.
A model to explain the enhanced transduction of AAV1/2
mixed virions is depicted in Fig. 8B and examines the viral entry
and trafficking fates of the AAV1 parental, AAV2 parental, and
AAV1/2 mixed virions. Transduction of C2C12 cells by AAV1
and AAV2 was relatively inefficient, in contrast to AAV1/2 mix-
tures at 1:3 and 1:19 ratios, at which transduction was 4-fold
higher than for AAV2 and 20-fold higher than for AAV1 (Fig.
7B). The results of the heparin inhibition studies demonstrated
AAV2 dependency on heparin to transduce C2C12 cells (11),
whereas AAV1 was not affected (Fig. 7B). The AAV1/2 mixtures
composed predominantly of AAV1 subunits were not sensitive to
the presence of soluble heparin but became sensitive as the com-
position of the virions changed to include more AAV2 subunits.
Interestingly, mosaic virions that were composed of more AAV 2
subunits demonstrated synergistic enhancement that correlated in
part to ability of the viral particle to bind HS.
However, this was not the sole reason for enhanced trans-
duction since, in the presence of HS, the transduction of
C2C12 cells by AAV1/2 (1:1) or AAV1/2 (1:3) was still 5-fold
higher than for either parent. It is possible that alternate re-
ceptors, coreceptors, or differences in trafficking between
AAV1 and AAV2 are contributing factors (Fig. 8B).
The trafficking pathways of AAV2 and AAV5 have been shown
to be different (2, 4, 9, 33). This raises the possibility that AAV1
not only uses a receptor different from that of AAV2 (Fig. 8B,
AAV1) but may also use a different trafficking route. Once bound
to the membrane by the heparin-binding contribution of AAV2,
the AAV1/2 mosaic virions internalize into endosomes, where the
small number of AAV1 subunits present in these mixtures may
exert a dominant trafficking phenotype, and direct the AAV1/2
particles efficiently through the cytoplasm to the nucleus (Fig. 8B,
AAV1/2). If this is the case, it would indicate a mechanism dif-
ferent from that proposed by Hauck and Xiao (17), who suggest
that to gain a property the virion must be composed of a majority
of that serotype structural component. In any case, additional
studies should allow one to map the region(s) of AAV1 contrib-
uting the enhancement factor observed in our and their mosaic
virions.
Conclusions and road map for new vector design. The
straightforward approach described here of mixing different
AAV helper plasmids to generate cross-dressed AAV virions
can be applied to all AAV serotypes and should allow for
continued analyses of AAV capsid assembly, receptor-medi-
ated binding, and virus trafficking. The transcapsidation of the
AAV serotypes defines subgroups based on sequence homol-
ogy, as well as structural relatedness. One advantage of this
approach is that it represents a method to functionally define
structural relatedness without having to perform crystallo-
graphic studies on all new serotypes. If this classification
scheme is applied to the newly described serotypes AAV7 and
AAV8, we would predict that by sequence homology they
would fall into subgroup A. It remains to be determined
whether this grouping would be maintained after structural
compatibility experiments similar to the ones described here
are performed. The outcome of these types of experiments
may further define the addition of new subgroups (i.e., se-
AAV5 subunits, to bind heparin is compromised. The interactions of AAV2 and AAV5 at the fivefold axis are also compatible with virion
formation (right). (B) Model of AAV1/AAV2 mosaic virus interactions with C2C12 cells resulting in synergistic transduction. The topology map
is used to depict the virion, with the blue subunits representing AAV1 and the red subunits representing AAV2. HS is represented as small
hexagons attached to HS proteoglycans (HSPG) (gray question marks). AAV1 does not interact with C2C12 cells through HSPG, whereas AAV2
does (left panel). The AAV2 portion of AAV1/2 binds HSPG through the threefold axis of symmetry, and an endosome forms around the virion
(middle panel). The trafficking of AAV1/2 through the cell may be controlled by the AAV1 portion of the virion by a route distinct from that used
by AAV2. AAV2 internalizes through coated vesicles and yet traffics to late endosomes and proteosomes where a larger proportion is degraded
(short arrow) and a portion is directed to the nucleus (long arrow) (right panel).
VOL. 78, 2004 TRANSCAPSIDATION OF AAV SEROTYPES DEFINES SUBGROUPS 4431
quence homology to subgroup A but structural compatibility to
subgroup C). It is possible that new and/or novel transduction
profiles will be observed upon mixing serotype 7 or 8 with the
members of subgroup A. Exploitation of this approach in gen-
erating custom-designed AAV vectors should be of significant
value to the field of gene therapy.
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